Tango Therapeutics (TNGX) Expected to Release Quarterly Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) is projected to issue its quarterly earnings data before the market opens on Monday, March 17th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $8.02 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The firm had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $7.84 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Trading Up 4.8 %

Tango Therapeutics stock opened at $1.95 on Friday. The business’s 50 day simple moving average is $2.63 and its 200 day simple moving average is $4.70. The company has a market cap of $210.81 million, a price-to-earnings ratio of -1.65 and a beta of 0.87. Tango Therapeutics has a 12 month low of $1.72 and a 12 month high of $12.02.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research report on Thursday, December 5th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.33.

Insider Transactions at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. This represents a 0.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 24,268 shares of company stock worth $72,561 in the last three months. Insiders own 6.30% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.